Erectile Dysfunction

They fell 10% to just under $1.1 billion, but the damage will be a lot more severe in the coming months as generic versions of the drug become more widely available.

Copycat competition is already hurting Zoloft (sertraline) and sales crashed 81% to $779 million.Exubera continues to disappointPfizer has reduced its full-year revenue estimates by $1.2 billion to $47-$48 million to reflect the loss of patent exclusivity for Norvasc, which came six months earlier than expected, and has adjusted its earnings forecast to $2.08-$2.15 per share, down from $2.18-$2.25.

Chief executive Jeffrey Kindler also noted that "the disappointing revenue performance" of Exubera (inhaled insulin) for diabetes is continuing and the firm will get more deeply involved in the more extensive market-development activities we now beli...

"In Malaysia, men with But the new tool, which is based on a four-point scale to identify the different grades of erection as the optimal treatment goal, will enable them to bravely talk about their sexual performance," he told a press conference here organised by Pfizer Malaysia.

The EHS, as the first-target level for the treatment of ED, was launched at the European Association of Urology annual meeting in Berlin, Germany last month.

Based on the Pfizer Global Better Sex Survey, published in the Journal of Sexual Medicine in December last year, he said 35 percent of the Malaysian respondents were found to have moderate ED and another 11 percent with severe ED.

The survey of the sexual habits of 12,558 men and women in 27 countries, including Thailand, Japan, Finland and the United States, also revealed that Malaysian women rated the importance of hardness of erection with sexual satisfaction, he said.